Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer.

CONCLUSION: Everolimus combined with endocrine therapy has significant clinical efficacy in patients with HR-positive/HER-2-negative advanced breast cancer, and can effectively improve the survival of patients with tolerable adverse reactions. PR+, absence of visceral metastases and sensitivity to endocrine therapy are the protective prognostic factors for PFS. PMID: 33277840 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33277840?dopt=Abstract

Source: Journal of B.U.ON. - December 7, 2020 Category: Cancer & Oncology Tags: J BUON Source Type: research